Novo Nordisk A/S shares rose last week despite market downturns, with a potential impact on stock price.
Stock AI’s forecasts:
🔴 -13.1% short-term ⬇️
🔴 -5.1% long-term ⬇️
Stock AI’s (NVO) Forecast get (+9.6% Profit)
StockAI’s analysis delivers real-world results. On 07 March 2024, $NVO ($137.5), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $124.3 (🔴-9.6%). Selling NVO on this signal yielded a +9.6% profit 💰💰.
NVO-Novo Nordisk A/S News
🟢 Novo Nordisk A/S shares rose 1.5% on Friday, trading as high as $126.13.
🔴 Novo Nordisk A/S share price dropped 0.2% during trading on Thursday, trading as low as $124.13.
🟢 Dakota Wealth Management lowered its stake in Novo Nordisk A/S by 5.0% in the 4th quarter.
🔴 Capital Investment Advisory Services LLC lowered its holdings in Novo Nordisk A/S by 8.3% in the 4th quarter.
🟢 Crestwood Advisors Group LLC increased its stake in Novo Nordisk A/S by 14.3% in the fourth quarter.
🔴 Novo Nordisk A/S was down 1.1% during mid-day trading on Thursday, trading as low as $122.55.
Novo Nordisk A/S stock has seen a mix of positive and negative news recently, impacting its price fluctuations. The rise in share price on Friday indicates some positive momentum for the company, while the decline in share price on Thursday may raise concerns among investors. The decrease in stakes by Dakota Wealth Management and Capital Investment Advisory Services could signal a lack of confidence in the stock, potentially leading to a decrease in price. However, the increase in stake by Crestwood Advisors Group LLC may provide some support for the stock price. Overall, the stock seems to be experiencing volatility due to various factors, and investors should stay informed about any further developments that could impact its price.
NVO-Novo Nordisk A/S Analyst Ratings
In recent analyst ratings for Novo Nordisk A/S (NYSE: NVO) stock, we have seen a mix of upgrades and downgrades:
📉 Morgan Stanley analysts downgraded their rating on Novo Nordisk A/S stock from Overweight to Equal Weight.
📉 Barclays analysts also downgraded their rating on Novo Nordisk A/S stock from Overweight to Equal Weight.
📈 Credit Suisse analysts upgraded their rating on Novo Nordisk A/S stock from Neutral to Outperform.
These recent analyst ratings indicate a mixed sentiment towards Novo Nordisk A/S stock, with some analysts becoming more bullish while others are taking a more cautious stance.
Sources:
1. MarketWatch
2. Bloomberg
3. Reuters
4. Nasdaq
5. Yahoo Finance
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
